Post-IPO Equity Funded Startups in United States
The largest disclosed post-IPO equity amount in the 50-row slice is KnowBe4’s $4.2B round dated 2022-09-20, which dwarfs the rest of the disclosed rounds:…
The largest disclosed post-IPO equity amount in the 50-row slice is KnowBe4’s $4.2B round dated 2022-09-20, which dwarfs the rest of the disclosed rounds: most other disclosed entries sit below $400M (for example, Biohaven Pharmaceutical at $302M on 2022-10-20 and Denali Therapeutics at $275M on 2022-10-19), while multiple deals fall into the single-digit millions (Thermogenesis at $2M on 2022-10-25; Creatd at $800K on 2022-09-19). At the other extreme of disclosed amounts, the smallest disclosed round is Creatd at $800K on 2022-09-19.
Timing and geography also cluster. The most recent entry is Vaxcyte on 2022-10-26, and the slice spans 2022-09-14 to 2022-10-26. Within that window, biotechnology is the most frequent sector (appearing in 24 of 50 rows), and several biotech/adjacent cities recur—San Francisco and Cambridge, Massachusetts each show multiple entries (e.g., Recursion Pharmaceuticals $150M on 2022-10-25; Axcella $34M on 2022-10-13; Immunovant $75M on 2022-10-04; Akero Therapeutics $200M on 2022-09-14). There are also 2 “undisclosed” amounts in the $375M–$302M range of headline activity (e.g., Vertiv on 2022-10-20; Salesforce on 2022-10-18).
Most recent rounds
50 shownRelated listings
Frequently asked
Which post-IPO equity round is the clear size outlier in this US set, and how does it compare with the rest of the disclosed amounts?
KnowBe4’s $4.2B round on 2022-09-20 is the only disclosed deal above $1B, while the next-highest disclosed amounts are far lower (e.g., Vaxcyte $600M on 2022-10-26 and Biohaven Pharmaceutical $302M on 2022-10-20). Several other disclosed rounds fall well below $10M, such as Creatd at $800K (2022-09-19) and Thermogenesis at $2M (2022-10-25).
How concentrated are the dates in the 50-row slice—are there multiple rounds landing in the same narrow window?
Yes. The list runs from 2022-09-14 (Akero Therapeutics $200M; IDEAYA Biosciences $80M) through 2022-10-26 (Vaxcyte $600M). A notable date cluster occurs around 2022-09-20, which includes multiple entries like KnowBe4 ($4.2B), Perficient ($4M), QuickLogic ($3M), and Therapeutic Solutions International ($10M).
Is biotechnology over-represented versus other sectors in this post-IPO equity slice?
Biotechnology appears in 24 of 50 rows, making it the dominant sector by a wide margin (for example, multiple biotech entries recur through late September and October: Denali Therapeutics $275M on 2022-10-19 and Amylyx Pharmaceuticals $246M on 2022-10-06). By contrast, other categories appear in far fewer rows (e.g., energy shows up at Dragonfly Energy $150M on 2022-10-10 and Amprius $200M on 2022-09-15, among others).
Are there city-level concentrations that repeat across different companies?
San Francisco shows repeated placements in the slice, including Recursion Pharmaceuticals $150M on 2022-10-25 (Salt Lake City is different, but the SF entries include Salesforce “undisclosed” on 2022-10-18, Dice Therapeutics $345M on 2022-10-17, and Spero Therapeutics $9M on 2022-09-22). Cambridge, Massachusetts also recurs with multiple biotech rounds such as Axcella $34M on 2022-10-13, InVivo Therapeutics $9M on 2022-10-07, and Akero Therapeutics $200M on 2022-09-14.
Do ‘undisclosed’ amounts meaningfully affect comparisons in this list?
Only 2 of the 50 rows are marked ‘undisclosed’ (Vertiv on 2022-10-20 and Colgate Palmolive on 2022-10-18). That means size comparisons among disclosed amounts are mostly intact, with the largest disclosed outlier still clearly anchored by KnowBe4 at $4.2B on 2022-09-20.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.